share_log

Gemina Labs Announces Addition to Its IP Portfolio

Gemina Labs Announces Addition to Its IP Portfolio

Gemina Labs宣布增加其知识产权组合
Accesswire ·  04/09 10:00

VANCOUVER, BC / ACCESSWIRE /April 9, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") today announces that it has licensed a novel biosensing architecture from the University of British Columbia.

不列颠哥伦比亚省温哥华/ACCESSWIRE /2024年4月9日/ Gemina Laboratories Ltd.(CSE: GLAB)(FRA: 8I7)(“公司” 或 “Gemina”)今天宣布,它已从不列颠哥伦比亚大学许可了一种新型生物传感架构。

This licence is the culmination of a programme of research commenced between Gemina and the University of British Columbia in 2021. It lays the foundation for expanding Gemina's technology portfolio to include point-of-care biosensors chips to enable low-cost, high-sensitivity detection of molecular amplification products, small molecules, and proteins. This opens the door to affordable single-use molecular assays for high-sensitivity diagnosis of infections like Mycobacterium tuberculosis with a novel test kit designed to meet the WHO high-priority target product profiles for new tuberculosis diagnostics. This is another step forward for Gemina to help meet the global health challenge to #EndTB2030. The licensed technology is the subject of a new patent application.

该许可证是Gemina和不列颠哥伦比亚大学于2021年启动的研究计划的最终成果。它为扩大Gemina的技术组合奠定了基础,使其包括即时生物传感器芯片,以实现对分子扩增产物、小分子和蛋白质的低成本、高灵敏度检测。这为经济实惠的一次性分子检测开启了大门,该方法用于对结核分枝杆菌等感染进行高灵敏度诊断,采用一种新的检测试剂盒,该试剂盒旨在满足世卫组织对新结核病诊断的高优先目标产品概况。这是Gemina向前迈出的又一步,旨在帮助迎接 #EndTB2030 的全球健康挑战。该许可技术是新专利申请的主题。

It's a programme of work that's highly consistent with Gemina's strategy of demonstrating that its core technology platform is widely applicable across point-of-care diagnostics, over and above the Company's first focus on improving the performance of lateral flow assays.

该工作计划与Gemina的战略高度一致,即证明其核心技术平台广泛适用于即时诊断,而该公司最初将重点放在改善侧流检测的性能上

Commenting today, Robert Greene, Gemina's CTO, said "One of the great privileges of my role is to be able to partner with exciting researchers at the forefront of their field. Our UBC partnership with Dr. Clifford is an outstanding example of industrial-academic collaboration and we're delighted with the research results that we've been able to achieve, which now form an important addition to Gemina's growing IP-engine".

Gemina的首席技术官罗伯特·格林在今天发表评论时说:“能够与处于各自领域最前沿的令人兴奋的研究人员合作,这是我工作的最大荣幸之一。我们在不列颠哥伦比亚大学与克利福德博士的合作是产学合作的杰出典范,我们对能够取得的研究结果感到高兴,这些结果现已成为Gemina不断增长的IP引擎的重要补充。”

On Behalf of the Board of Directors

代表董事会

Brian Firth
CEO
Gemina Laboratories Ltd.

Brian Firth
首席执行官
Gemina 实验室有限公司

About Gemina Laboratories Ltd.

关于 Gemina 实验室有限公司

Gemina Labs is a point-of-care diagnostics technology company with a family of transformative, patented, proprietary technologies that power next-generation testing platforms for a wide range of diagnostic targets that affect human health and wellness. Our technology drives testing platforms that are portable, affordable, accurate, and simple to use. Our development pipeline includes proprietary designs for multiple point-of-care diagnostic form factors, including lateral flow assays, biosensors, and molecular assays. Additional information on the Company can be found at

Gemina Labs是一家即时诊断技术公司,拥有一系列变革性、专利的专有技术,为影响人类健康和保健的各种诊断靶标的下一代测试平台提供支持。我们的技术推动了便携式、经济实惠、准确且易于使用的测试平台。我们的开发管道包括针对多种床旁诊断外形规格的专有设计,包括侧流检测、生物传感器和分子检测。有关该公司的其他信息可以在以下网址找到

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

加拿大证券交易所及其监管服务提供商(该术语在加拿大证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

Forward-Looking Statements

前瞻性陈述

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

本新闻稿包括前瞻性信息和陈述,其中可能包括但不限于有关或推断公司未来业务、运营、财务业绩、前景以及其他计划、意图、预期、估计和信念的信息和陈述。此类陈述包括有关任何拟议交易或合同的预期条款的陈述。不纯粹是历史事实的信息和陈述是前瞻性陈述。前瞻性信息和陈述涉及假设以及已知和未知的风险、不确定性以及其他因素,这些因素可能导致公司的实际事件、业绩、业绩或成就与本文前瞻性信息和陈述所表达或暗示的未来事件、业绩、业绩和成就存在重大差异。尽管公司认为此处的任何前瞻性信息和陈述都是合理的,但鉴于所使用的假设以及此类信息和陈述中固有的重大风险和不确定性,无法保证任何此类前瞻性信息和陈述会被证明是准确的,因此,建议读者依赖自己对此类风险和不确定性的评估,不应过分依赖此类前瞻性信息和陈述。此外,该公司目前无法完全量化Covid-19疫情将对其运营产生的影响,并认识到某些可能的情况可能会影响未来的计划或假设业绩。因此,此处的任何前瞻性信息和陈述均截至本文发布之日作出,除非适用法律要求,否则公司不承担任何义务,也不打算更新或修改此处的任何前瞻性信息和陈述,也不打算更新实际事件或结果可能或确实与本文任何前瞻性信息和陈述中预测的不同的理由,无论是由于新信息、未来事件或业绩还是其他原因造成的适用的法律。

For more information regarding the Company, please contact:

如需了解有关本公司的更多信息,请联系:

Gemina Laboratories Ltd
Brian Firth, Chief Executive Officer
Email: investor@geminalabs.com

Gemina 实验室有限公司
首席执行官 Brian Firth
电子邮件:investor@geminalabs.com

SOURCE: Gemina Laboratories Ltd.

来源:Gemina 实验室有限公司


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发